Allakos Inc

NASDAQ ALLK

Data sourced from

and

Download Data

Allakos Inc Goodwill and Intangible Assets for the Trailing 12 Months (TTM) ending March 31, 2024

Allakos Inc Goodwill and Intangible Assets is NA for the Trailing 12 Months (TTM) ending March 31, 2024. Goodwill and Intangible Assets represent the combined value of goodwill and intangible assets on a company's balance sheet.

NASDAQ: ALLK

Allakos Inc

CEO	Dr. Robert Alexander Ph.D.
IPO Date	July 19, 2018
Location	United States
Headquarters	975 Island Drive, Redwood City, CA, United States, 94065
Employees	131
Sector	Healthcare
Industry	Biotechnology

Description

Allakos Inc., a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company's lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications. The company was incorporated in 2012 and is headquartered in San Carlos, California.

Key trends